

## Daily Market Review

8<sup>th</sup> April, 2011

## Indices

BSE SENSEX	19591.18	-21.02	0.10%
NIFTY	5885.70	-6.05	0.10%
FTSE 100	6031.66	-9.65	0.16%
NASDAQ	2812.59	12.65	0.45%
S&P	1337.59	2.00	0.15%
NIKKEI	9590.93	6.71	0.07%
HANG SENG	24281.80	-2.42	0.01%

## Top Gainers for the Day (BSE 100)

Indian Hotels	6.98%
IVRS Infra	5.70%
GMR Infra	5.15%
Unitech	5.08%
HPCL	3.17%

## Top Losers for the Day (BSE100)

Sesa Goa	3.07%
NTPC	2.61%
ONGC	2.10%
Cairn India	2.02%
TCS	2.00%

## Currency Market

\$/Re	44.20	0.08	0.02%
Euro/Re	63.10	-0.07	0.04%

## Commodity Market

Crude Oil	\$122.03	-0.26	0.21%
Gold	\$1464.22	7.32	0.58%

## FII ACTIVITY

Rs. Crore	Buy	Sell	Net
FII	2675.95	2455.36	220.59

## News Headlines

**Sensex falls**

Indian stocks fell for the third day, as exporter made loss because of weak dollar against Rupee. Expectations of Rupee appreciation sustained in the market raising concerns for Software Exporters.

Sensex lost 21.02 points, to close at 19591.18. 17 of the 30 stocks declined. Nifty shed 6.05 points to close at 5885.70.

Companies on the benchmark traded at an average 15.5 times of their estimated earnings as compared to 21.5 times in March 2010.

**Maruti Suzuki to boost spending by 33%**

Nation's biggest Car Maker, Maruti Suzuki India Ltd., will increase their spending by 33% this year to expand its capacity and to develop new models to face rising competition from Hyundai Motor Co. and Toyota Motor Co.

Past few years, spending were about Rs.3000 crore, but this year as they plan to expand capacity by 21%, it can go up to Rs.4000 crore.

**Glenmark inked licensing pact with Canadian Company**

Glenmark, Mumbai based drug maker, signed a pact with Canada's ImmanenceIntegrable Dermo Correction Inc. to market anti-ageing creams and lotions in eight countries including India.

Glenmark is present in dermatology segment and already has some ointments and lotions like Candid for skin infections which is the top selling medicine in the category.

**IFCI raises stake in Koutons Retail India**

Financial Services Company IFCI Ltd. has increased its stake in debt laden, Koutons Retail India Ltd. from 5.89% to 10.24% by invoking its pledged shares.

### Zydus got USFDA nod for new diabetes drug

Cadilla Healthcare Ltd. also known as Zydus Cadilla got USFDA approval for its new drug ZYGK1, meant for treatment of diabetes. The new molecular entity is orally administered, Glucokinase activated small molecule. Firm will shortly start with phase 1 clinical trials for ZYGK1.

### Silver top performing metal, so far this year

Silver has outshone other metals by rising 28% so far this year, when gold has just gone up by 2.8%. the gold silver ratio, which tells how many ounces of silver are needed to buy an ounce of gold, fell to its lowest since 1983 this week to below 37, against 63 a year ago.

#### Our Team

Mrunmay Das	<a href="mailto:mrunmay@dascap.com">mrunmay@dascap.com</a>	Ph:91-80-28440501-Ext 31	Mob: 91-9845026333
Arun Thirumalai	<a href="mailto:arun@dascap.com">arun@dascap.com</a>	Ph:91-80-28440501-Ext 32	Mob: 91-9740077809

#### Disclaimer

This report is not directed to, or intended to or use by, any person or entity who is a citizen of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Das Capital Management and Advisors Pvt Ltd to any registration or licensing requirements within such jurisdiction. This report is provided for information purposes only. The report is based on information generally available and is deemed reliable but no assurance is given as to its accuracy or completeness. Das Capital Management and Advisors Pvt Ltd is not accountable for any decision based on the contents of this report. Neither the information nor the opinions contained are to be construed as an offer to buy and sell securities mentioned above. This report is not to be relied upon in substitution for the exercise of independent judgment. Investors should judge the suitability of the securities to their needs. Das Capital Management and Advisors Pvt Ltd makes no representation that the preparation or distribution of this report is in compliance with the legal requirements or regulations of any jurisdiction, and it disclaims all liability in case the preparation or distribution of this report is found to be non-compliant with any such legal requirements or regulations. Das Capital Management and Advisors Pvt Ltd may, to the extent permitted by law, act upon or use the information or opinions presented herein, or the research or analysis on which they are based, before the material is published.